Acadia Pharmaceuticals
ACAD
267 hedge funds and large institutions have $2.99B invested in Acadia Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 104 increasing their positions, 73 reducing their positions, and 55 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 73
10% more call options, than puts
Call options by funds: $39.4M | Put options by funds: $35.9M
0.9% more ownership
Funds ownership: 97.16% → 98.06% (+0.9%)
7% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 55
3% less funds holding
Funds holding: 276 → 267 (-9)
40% less capital invested
Capital invested by funds: $4.99B → $2.99B (-$2.01B)
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$63.8M |
| 2 |
Squarepoint
New York
|
+$18.1M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$16.4M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$15.6M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.2M |
| 3 |
D.E. Shaw & Co
New York
|
-$27.6M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$25.8M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$25.3M |
ACAD Hedge Fund Activity: Q1 2024 in Review
267 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2024, worth a combined $2.99B — down 40% from $4.99B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of ACAD and 51 opened new positions — a net loss of 4 holders — while 73 trimmed existing stakes and 104 added.
The largest buyer was RTW Investments, adding an estimated $63.8M. The largest seller was Fidelity Investments, cutting an estimated $31.5M.
- 267 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2024, down from 276 in Q4 2023.
- Funds reported $2.99B of Acadia Pharmaceuticals stock for Q1 2024, down 40% quarter-over-quarter.
- 51 funds opened new Acadia Pharmaceuticals positions in Q1 2024 and 55 closed out, a net change of -4 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2024 was RTW Investments, an estimated $63.8M added.
- The largest Acadia Pharmaceuticals seller in Q1 2024 was Fidelity Investments, an estimated $31.5M sold.
Based on aggregated 13F filings for Q1 2024.